Vane Percy lands brain cancer brief

Schering-Plough is using Vane Percy & Associates to advise on UK comms for brain cancer brand Temodal.

S-P turned to Vane Percy – with which it already has long-standing links – after the end of its relationship with Red Door Communications on both Temodal and ovarian cancer brand Caelyx.

The company only hired Red Door four months ago (PRWeek, 19 January), but both sides said this week that the appointment was merely for projects which had already ended.

It is a crucial time for Temodal – on 28 April, NICE recommended against its use for newly diagnosed brain cancer patients. A similarly negative appraisal was made of Link Pharmaceuticals’ Gliadel Implants, also for the treatment of brain cancer (PRWeek, 12 May).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in